Search Site
  • 0
    My Cart

    Click Here to Find How Many Items You Have Added:)

    image loader

    Adding item(s) to cart......

Home >> Signaling Pathways >> Tyrosine Kinase

Tyrosine Kinase

Products for  Tyrosine Kinase

  1. Cat.No. Product Name Information
  2. GC35652 CEP-28122 mesylate salt CEP-28122 mesylate salt, a diaminopyrimidine derivative, is a potent, selective, and orally bioavailable ALK inhibitor, with an IC50 value of 1.9 nM for recombinant ALK kinase activity. CEP-28122 has antitumor activity in experimental models of ALK-positive human cancers. CEP-28122 mesylate salt has good pharmacodynamic and pharmacokinetic activity. CEP-28122 mesylate salt Chemical Structure
  3. GC15273 CEP-37440 FAK/ALK inhibitor,potent and selective CEP-37440 Chemical Structure
  4. GC19102 CEP-40783

    RXDX-106

     CEP-40783 is a potent, selective and orally available inhibitor of AXL and c-Met with IC50 values of 7 nM and 12 nM, respectively. CEP-40783 Chemical Structure
  5. GC11209 Cerdulatinib (PRT062070)

    PRT062070, PRT2070

     Cerdulatinib (PRT062070) (PRT062070) is a selective Tyk2 inhibitor with an IC50 of 0.5 nM. Cerdulatinib (PRT062070) (PRT062070) also is a dual JAK and SYK inhibitor with IC50s of 12, 6, 8 and 32 for JAK1, 2, 3 and SYK, respectively. Cerdulatinib (PRT062070) Chemical Structure
  6. GC45789 Ceritinib-d7

    LDK 378-d7

     An internal standard for the quantification of ceritinib Ceritinib-d7 Chemical Structure
  7. GC34217 Cetuximab (C225)

    C225

     Cetuximab is a chimeric monoclonal antibody generated from fusion of the variable region of the murine anti-EGFR monoclonal antibody M225 and the human IgG1 constant region. Cetuximab (C225) Chemical Structure
  8. GC63429 Cevidoplenib

    SKI-O-703

     Cevidoplenib (SKI-O-703) is an orally active and selective spleen tyrosine kinase (Syk) inhibitor. Cevidoplenib Chemical Structure
  9. GC63455 Cevidoplenib dimesylate

    SKI-O-703 dimesylate

     Cevidoplenib is an orally available inhibitor of spleen tyrosine kinase (Syk), with potential anti-inflammatory and immunomodulating activities. Cevidoplenib dimesylate Chemical Structure
  10. GC34528 cFMS Receptor Inhibitor II cFMS Receptor Inhibitor II is a CSF1R kinase inhibitor. cFMS Receptor Inhibitor II Chemical Structure
  11. GC65976 cFMS Receptor Inhibitor IV cFMS Receptor Inhibitor IV (Compound 42) is a potent cFMS inhibitor with an IC50 of 0.017 μM. cFMS Receptor Inhibitor IV Chemical Structure
  12. GC31726 cFMS-IN-2 cFMS-IN-2 is a FMS kinase inhibitor with an IC50 of 0.024 μM. cFMS-IN-2 Chemical Structure
  13. GC33064 CG-806 (Luxeptinib)

    CG-806

     CG-806 (Luxeptinib) (CG-806) is an orally active, reversible, first-in-class, non-covalent and potent pan-FLT3/pan-BTK inhibitor. CG-806 (Luxeptinib) induces cell cycle arrest, apoptosis or autophagy in acute myeloid leukemia cells. CG-806 (Luxeptinib) Chemical Structure
  14. GC15950 CGP 52411

    CGP 52411, 4,5-Dianilinophthalimide

     EGFR inhibitor CGP 52411 Chemical Structure
  15. GC18438 CGP 77675 CGP 77675 is an inhibitor of Src family kinases (SFKs) that blocks the phosphorylation of peptide substrates and autophosphorylation of purified c-Src (IC50s = 5-20 and 40 nM, respectively). CGP 77675 Chemical Structure
  16. GC48992 CGP 77675 (hydrate) An inhibitor of Src family kinases CGP 77675 (hydrate) Chemical Structure
  17. GC14650 CGP60474 A CDK inhibitor CGP60474 Chemical Structure
  18. GC10759 CH5183284 (Debio-1347)

    Debio 1347

     CH5183284 (Debio-1347) (Debio 1347) is an orally available and selective FGFR inhibitor with IC50s of 9.3, 7.6, and 22 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively. CH5183284 (Debio-1347) Chemical Structure
  19. GC16025 CH5424802

    Alectinib, RO5424802

     CH5424802 (CH5424802) is a potent, selective, and orally available ALK inhibitor with an IC50 of 1.9 nM and a Kd value of 2.4 nM (in an ATP-competitive manner), and also inhibits ALK F1174L and ALK R1275Q with IC50s of 1 nM and 3.5 nM, respectively. CH5424802 demonstrates effective central nervous system (CNS) penetration. CH5424802 Chemical Structure
  20. GC33112 CH7057288 CH7057288 is a potent and selective TRK inhibitor. CH7057288 Chemical Structure
  21. GC25219 CH7233163 CH7233163 is a non-covalent ATP competitive inhibitor of EGFR-tyrosine kinase with antitumor activities against tumor with EGFR-Del19/T790M/C797S. CH7233163 Chemical Structure
  22. GC62145 Chiauranib

    CS2164

     Chiauranib (CS2164) is an orally active multi-target inhibitor against tumor angiogenesis. Chiauranib potently inhibits the angiogenesis-related kinases (VEGFR1, VEGFR2, VEGFR3, PDGFRα and c-Kit), mitosis-related kinase Aurora B, and chronic inflammation-related kinase CSF-1R, with IC50 values ranging from 1-9 nM. Chiauranib has strongly anticancer effects. Chiauranib Chemical Structure
  23. GC15739 CHIR-124 Chk1 inhibitor,novel and potent CHIR-124 Chemical Structure
  24. GC32979 Chloropyramine hydrochloride Chloropyramine hydrochloride is a histamine receptor H1 antagonist which can also inhibit the biochemical function of VEGFR-3 and FAK. Chloropyramine hydrochloride Chemical Structure
  25. GC17294 CHMFL-ABL-053 BCR-ABL inhibitor CHMFL-ABL-053 Chemical Structure
  26. GC35682 CHMFL-ABL/KIT-155

    CHMFL-ABL-KIT-155

     CHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155; compound 34) is a highly potent and orally active type II ABL/c-KIT dual kinase inhibitor (IC50s of 46 nM and 75 nM, respectively), and it also presents significant inhibitory activities to BLK (IC50=81 nM), CSF1R (IC50=227 nM), DDR1 (IC50=116 nM), DDR2 (IC50=325 nM), LCK (IC50=12 nM) and PDGFRβ (IC50=80 nM) kinases. CHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155) arrests cell cycle progression and induces apoptosis. CHMFL-ABL/KIT-155 Chemical Structure
  27. GC33020 CHMFL-BMX-078 (CHMFL-BMX 078)

    CHMFL-BMX 078

     CHMFL-BMX-078 (CHMFL-BMX 078) is a highly potent and selective type II irreversible BMX kinase inhibitor with an IC50 of 11 nM. CHMFL-BMX-078 (CHMFL-BMX 078) Chemical Structure
  28. GC35684 CHMFL-EGFR-202 CHMFL-EGFR-202 is a potent, irreversible inhibitor of epidermal growth factor receptor (EGFR) mutant kinase, with IC50s of 5.3 nM and 8.3 nM for drug-resistant mutant EGFR T790M and WT EGFR kinases, respectively. CHMFL-EGFR-202 exhibits ?10-fold selectivity for EGFR L858R/T790M against the EGFR wild-type in cells. CHMFL-EGFR-202 adopts a covalent “DFG-in-C-helix-out” inactive binding conformation with EGFR, with strong antiproliferative effects against EGFR mutant-driven nonsmall-cell lung cancer (NSCLC) cell lines. CHMFL-EGFR-202 Chemical Structure
  29. GC35685 CHMFL-KIT-033 CHMFL-KIT-033 is a potent and selective inhibitor of c-KIT T670I mutant for gastrointestinal stromal tumors (GISTs), with an IC50 of 0.045 μM. CHMFL-KIT-033 Chemical Structure
  30. GN10327 Chrysophanol

    Chrysophanic Acid, NSC 37132, NSC 646567, Turkey Rhubarb

     Chrysophanol Chemical Structure
  31. GC43268 Cinnamtannin B-1

    LDN-0022358

     Cinnamtannin B-1 is a proanthocyanidin polyphenol originally isolated from cinnamon bark that has antioxidant properties. Cinnamtannin B-1 Chemical Structure
  32. GC74542 Cinrebafusp alfa

    PRS 343

     Cinrebafusp alfa (PRS 343) is a high affinity CD137/HER2 bispecfic anticalin-based drug. Cinrebafusp alfa Chemical Structure
  33. GC32713 Cintirorgon (LYC-55716)

    LYC-55716

     Cintirorgon (LYC-55716) (LYC-55716) is a first-in-class, selective and orally bioavailable RORγ agonist. Cintirorgon (LYC-55716) (LYC-55716) modulates gene expression of RORγ expressing T lymphocyte immune cells, resulting in enhanced effector function, as well as decreased immunosuppression, resulting in decreased tumor growth, and improved survival. Cintirorgon (LYC-55716) Chemical Structure
  34. GC39485 CK2/ERK8-IN-1 A dual inhibitor of CK2 and ERK8 CK2/ERK8-IN-1 Chemical Structure
  35. GC17790 CL-387785 (EKI-785)

    EKB-785, EKI-785, WAY-EKI-785

     CL-387785 (EKI-785)(EKI785; WAY-EKI 785) is an irreversible inhibitor of EGFR with IC50 of 370 pM. CL-387785 (EKI-785) Chemical Structure
  36. GC73224 CLK1-IN-3 CLK1-IN-3 (compound 10ad) is a potent and selective Clk1 inhibitor, with an IC50 of 5 nM and over 300-fold selectivity for Dyrk1A. CLK1-IN-3 Chemical Structure
  37. GC68888 CMX-2043

    CMX-2043 is a new analogue of alpha-lipoic acid. It has antioxidant properties and can activate insulin receptor kinase, soluble tyrosine kinase, and promote Akt phosphorylation. CMX-2043 has shown protective effects in a rat model of ischemia-reperfusion injury (IRI).

     CMX-2043 Chemical Structure
  38. GC11264 CNX-2006

    mutant-EGFR inhibitor, selective and irreversible

     CNX-2006 Chemical Structure
  39. GC14695 CO-1686 (AVL-301)

    AVL-301;CNX-419; Rociletinib

     A selective inhibitor of mutant EGFR CO-1686 (AVL-301) Chemical Structure
  40. GC12837 Compound 56 A potent EGFR inhibitor Compound 56 Chemical Structure
  41. GC46123 Comprehensive Kinase Screening Library For screening of a variety of kinase inhibitors Comprehensive Kinase Screening Library Chemical Structure
  42. GC35728 Conteltinib

    CT-707

     Conteltinib (CT-707) is a multi-kinase inhibitor targeting FAK, ALK, and Pyk2. Conteltinib exerts significant inhibitory effect on FAK with an IC50 of 1.6 nM. Conteltinib Chemical Structure
  43. GC33352 CP-547632 A potent inhibitor of VEGFR2 and bFGF CP-547632 Chemical Structure
  44. GC38575 CP-547632 hydrochloride CP-547632 hydrochloride is an orally active, ATP-competitive and potent VEGFR-2 and FGF kinases inhibitor with IC50s of 11 nM and 9 nM, respectively. CP-547632 hydrochloride is selective for VEGFR2 and bFGF over EGFR, PDGFRβ, and related tyrosine kinases (TKs). CP-547632 hydrochloride has antitumor efficacy. CP-547632 hydrochloride Chemical Structure
  45. GC60726 CP-547632 TFA CP-547632 TFA is an orally active, ATP-competitive and potent VEGFR-2 and FGF kinases inhibitor with IC50s of 11 nM and 9 nM, respectively. CP-547632 TFA is selective for VEGFR2 and bFGF over EGFR, PDGFRβ, and related tyrosine kinases (TKs). CP-547632 TFA has antitumor efficacy. CP-547632 TFA Chemical Structure
  46. GC12980 CP-673451 PDGFRα/β inhibitor,potent and selective CP-673451 Chemical Structure
  47. GC13091 CP-724714 HER2 inhibitor,potent and selective CP-724714 Chemical Structure
  48. GC62274 CPL304110 CPL304110 is a potent, orally active and selective inhibitor of fibroblast growth factor receptors FGFR (1-3), with IC50 values of 0.75 nM, 0.5 nM, and 3.05 nM for FGFR (1-3), respectively. CPL304110 Chemical Structure
  49. GC14906 Crenolanib (CP-868596)

    CP-868596;CP 868596;CP868596

     Crenolanib (CP-868596) is a potent and selective inhibitor of wild-type and mutant isoforms of the class III receptor tyrosine kinases FLT3 and PDGFRα/β with Kds of 0.74 nM and 2.1 nM/3.2 nM, respectively. Crenolanib (CP-868596) Chemical Structure
  50. GC12616 Crizotinib hydrochloride

    inhibitor of the c-Met kinase and the NPM-ALK

     Crizotinib hydrochloride Chemical Structure
  51. GC38412 Crotonoside

    2-Hydroxyadenosine, Isoguanine riboside, Isoguanosine, NSC 12161

     Crotonoside is a FLT3 and HDAC3/6 inhibitor that can be used to study acute myeloid leukemia (AML). Crotonoside Chemical Structure
  52. GC25313 CS-2660 (JNJ-38158471) CS-2660 (JNJ-38158471) is a well tolerated, orally available, highly selective VEGFR-2 inhibitor with IC50 of 40 nM. CS-2660 (JNJ-38158471) also inhibits closely related tyrosine kinases such as RET (c-RET) and Kit (c-Kit) with IC50 of 180 nM and 500 nM，while it has no significant activity (>1 microM) against VEGFR-1 and VEGFR-3. CS-2660 (JNJ-38158471) Chemical Structure
  53. GC33241 CSF1R-IN-1 CSF1R-IN-1 is a CSF1R inhibitor with an with an IC50 of 0.5 nM. CSF1R-IN-1 Chemical Structure
  54. GC64961 CSF1R-IN-2

    CSF1R-IN-2, CSF1R Inhibitor 2, Elzovantinib

     CSF1R-IN-2 (compound 5) is an oral-active inhibitor of SRC, MET and c-FMS, with IC50 values of 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively. CSF1R-IN-2 Chemical Structure
  55. GC73906 CSF1R-IN-24 CSF1R-IN-24 (Example 134) is an orally active CSF1R inhibitor. CSF1R-IN-24 Chemical Structure
  56. GC64805 CSF1R-IN-3 CSF1R-IN-3 (compound 21) is a potent and orally active CSF-1R inhibitor (IC50=2.1 nM). CSF1R-IN-3 is a potent antiproliferative activity against colorectal cancer cells. CSF1R-IN-3 inhibits the progression of colorectal cancer by suppressing the migration of macrophages, reprograming M2-like macrophages to the M1 phenotype, and enhancing the antitumor immunity. CSF1R-IN-3 Chemical Structure
  57. GC35753 CT-721 CT-721 is a potent and time-dependent Bcr-Abl kinase inhibitor with an IC50 of 21.3 nM for wild-type Bcr-Abl kinase, and possesses anti-chronic myeloid leukemia (CML) activities. CT-721 Chemical Structure
  58. GC67774 CT52923 CT52923 Chemical Structure
  59. GC50076 CTA 056 ITK inhibitor CTA 056 Chemical Structure
  60. GC17637 CTX0294885 Pan-kinase inhibitor CTX0294885 Chemical Structure
  61. GC16008 CUDC-101 A multi-target inhibitor of HDACs, EGFR, and HER2 CUDC-101 Chemical Structure
  62. GC38180 Cyasterone Cyasterone Chemical Structure
  63. GC13780 Cyclotraxin B TrkB receptor antagonist Cyclotraxin B Chemical Structure
  64. GC91419 CYY292 CYY292 is an inhibitor of PDGFRα, PDGFRβ, FGFR1, -2, and -3, (IC50s = 5.35, 4.6, 28, 28, and 78 nM, respectively). CYY292 Chemical Structure
  65. GC16731 CZC 54252 hydrochloride CZC 54252 hydrochloride is a potent and selective LRRK2 inhibitor with IC50s of 1.28 nM and 1.85 nM for wild-type and G2019S LRRK2, respectively. CZC 54252 hydrochloride Chemical Structure
  66. GC16038 CZC-25146 LRRK2 inhibitor CZC-25146 Chemical Structure
  67. GC35792 CZC-25146 hydrochloride CZC-25146 hydrochloride is a potent LRRK2 inhibitor with IC50 values of 4.76 nM and 6.87 nM for wild-type LRRK2 and G2019S LRRK2, respectively. CZC-25146 hydrochloride Chemical Structure
  68. GC33351 CZC-8004 (CZC-00008004)

    Dianilinopyrimidine-01

     CZC-8004 (CZC-00008004) (CZC-00008004), an aminopyrimidine, is a pan-kinase inhibitor. CZC-8004 (CZC-00008004) can bind a range of tyrosine kinases, including EGFR and VEGFR2 with IC50 values of 650 and 437 nM, respectively. CZC-8004 (CZC-00008004) Chemical Structure
  69. GC43433 D-Glucosamine-6-sulfate

    GlcN-6S

     D-Glucosamine-6-sulfate is a naturally occurring glycosaminoglycan. D-Glucosamine-6-sulfate Chemical Structure
  70. GC62712 DA-JC4 DA-JC4 is a dual GLP-1/GIP receptor agonist and can be used for the research of neurological disease and insulin signaling pathways. DA-JC4 Chemical Structure
  71. GC10225 Dacomitinib (PF299804, PF299)

    PF-00299804; PF-299804; PF 299804; PF 00299804

     Dacomitinib (PF299804, PF299) (PF-00299804) is a specific and irreversible inhibitor of the ERBB family of kinases with IC50s of 6 nM, 45.7 nM and 73.7 nM for EGFR, ERBB2, and ERBB4, respectively. Dacomitinib (PF299804, PF299) Chemical Structure
  72. GC72889 Dacomitinib hydrate

    PF-00299804 hydrate; PF-299804 hydrate

     Dacomitinib (PF-00299804) drate is an orally active, irreversible pan-ErbB inhibitor. Dacomitinib hydrate Chemical Structure
  73. GC73131 Dalmelitinib Dalmelitinib is an orally active selective c-Met kinase inhibitor (IC50: 2.9 nM) that binds to the ATP-binding region of c-Met. Dalmelitinib Chemical Structure
  74. GC15211 Damnacanthal p56lck tyrosine kinase inhibitor Damnacanthal Chemical Structure
  75. GC15217 Danusertib (PHA-739358)

    PHA-739358

     A pan-Aurora kinase and Abl inhibitor Danusertib (PHA-739358) Chemical Structure
  76. GN10336 Daphnetin

    7,8-Dihydroxycoumarin, NSC 633563

     Daphnetin Chemical Structure
  77. GC74027 DAS-5-oCRBN DAS-5-oCRBN is a selective and potent PROTAC degrader of c-Src kinase. DAS-5-oCRBN Chemical Structure
  78. GC15568 Dasatinib (BMS-354825)

    BMS 354825, Sprycel

     An inhibitor of Abl and Src Dasatinib (BMS-354825) Chemical Structure
  79. GC35812 Dasatinib hydrochloride A potent and dual AblWT/Src inhibitor Dasatinib hydrochloride Chemical Structure
  80. GC15884 Dasatinib Monohydrate Inhibitor of ABL, SRC, KIT, PDGFR, and other tyrosine kinases. Dasatinib Monohydrate Chemical Structure
  81. GC45687 Dasatinib N-oxide A major metabolite of dasatinib Dasatinib N-oxide Chemical Structure
  82. GC62569 DBPR112 DBPR112 is an orally active furanopyrimidine-based EGFR inhibitor with IC50s of 15 nM and 48 nM for EGFRWT and EGFRL858R/T790M, respectively. DBPR112 can occupy the ATP-binding site. DBPR112 has significant antitumor efficacy. DBPR112 Chemical Structure
  83. GC14007 DCC-2036 (Rebastinib)

    DCC-2036

     DCC-2036 (Rebastinib) (DCC-2036) is an orally active, non-ATP-competitiveBcr-Abl inhibitor for Abl1WT and Abl1T315I with IC50s of 0.8 nM and 4 nM, respectively. DCC-2036 (Rebastinib) also inhibits SRC, KDR, FLT3, and Tie-2, and has low activity to seen towards c-Kit. DCC-2036 (Rebastinib) Chemical Structure
  84. GC11171 DCC-2618

    DCC2618;DCC 2618

     A dual inhibitor of c-Kit and c-MET DCC-2618 Chemical Structure
  85. GC39623 DCC-3014

    DCC-3014

     DCC-3014 (DCC-3014) is a c-FMS (CSF-IR) and c-Kit dual inhibitor extracted from patent WO2014145025A2, Compound Example 10, has IC50s of <0.01 μM and 0.1-1 μM, respectively. DCC-3014 Chemical Structure
  86. GC73579 DDO-2728 DDO-2728 (compound 19) is a selective AlkB homologue 5 (ALKBH5) inhibitor with an IC50 of 2.97 μM. DDO-2728 Chemical Structure
  87. GC33361 DDR Inhibitor DDR Inhibitor is a potent discoidin domain receptor (DDR) inhibitor, with an IC50 of 3.3 nM for DDR2, and shows 53% inhibition on DDR1 at 1.5 nM. DDR Inhibitor Chemical Structure
  88. GC17365 DDR1-IN-1 selective DDR1 receptor tyrosine kinase inhibitor DDR1-IN-1 Chemical Structure
  89. GC35822 DDR1-IN-1 dihydrochloride DDR1-IN-1 dihydrochloride is a potent and selective DDR1 receptor tyrosine kinase inhibitor with an IC50 of 105 nM; 4-fold less potent for DDR2 (IC50 = 413 nM). DDR1-IN-1 dihydrochloride Chemical Structure
  90. GC31724 DDR1-IN-2

    7rh

     DDR1-IN-2 (DDR1-IN-2) is a potent inhibitor of discoidin domain receptor 1 (DDR1), with an IC50 of 13.1 nM, and also less potently inhibits DDR2, with an IC50 of 203 nM. DDR1-IN-2 Chemical Structure
  91. GC33297 DDR1-IN-3 DDR1-IN-3 is a selective Discoidin Domain Receptor 1 (DDR1) inhibitor, with an IC50 value of 9.4 nM. DDR1-IN-3 also inhibits TRK family. DDR1-IN-3 Chemical Structure
  92. GC64268 DDR1-IN-4 DDR1-IN-4 (Compound 2.45) is a selective and potent Discoidin Domain Receptor 1 (DDR1) autophosphorylation inhibitor, with IC50 values of 29 nM and 1.9 μM for DDR1 and DDR2, respectively. DDR1-IN-4 Chemical Structure
  93. GC65378 DDR1-IN-5 DDR1-IN-5 is a selective Discoidin Domain Receptor family, member 1 (DDR1) inhibitor with an IC50 of 7.36 nM. DDR1-IN-5 inhibits auto-phosphorylation DDR1b (Y513) with an IC50 of 4.1 nM. DDR1-IN-5 has anti-cancer activity. DDR1-IN-5 Chemical Structure
  94. GC66476 DDR1-IN-6 DDR1-IN-6 is a selective Discoidin Domain Receptor family, member 1 (DDR1) inhibitor with an IC50 of 9.72 nM. DDR1-IN-6 inhibits auto-phosphorylation DDR1b (Y513) with an IC50 of 9.7 nM. DDR1-IN-6 has anti-cancer activity. DDR1-IN-6 Chemical Structure
  95. GC73659 DDR1/2 inhibitor-2 DDR1/2 inhibitor-2 (Example 31) is a DDR1/DDR2 inhibitor, with IC50 values less than 100 nM. DDR1/2 inhibitor-2 Chemical Structure
  96. GC70345 DDR2-IN-1 DDR2-IN-1 is potent DDR2 inhibitor with an IC50 of 26 nM. DDR2-IN-1 Chemical Structure
  97. GC16813 Defactinib

    PF-04554878, VS-6063

    FAK phosphorylation inhibitor

     Defactinib Chemical Structure
  98. GC35827 Defactinib hydrochloride

    VS-6063 hydrochloride; PF 04554878 hydrochloride

     A novel FAK inhibitor Defactinib hydrochloride Chemical Structure
  99. GC47182 Dehydrolithocholic Acid

    3-keto LCA, 3-keto Lithocholate, 3-keto Lithocholic Acid, 3-KLCA, 3-oxo LCA, 3-oxo Lithocholate, 3-oxo Lithocholic Acid

     Dehydrolithocholic Acid (Dehydrolithocholic acid), a bile acid metabolite, inhibits the diferentiation of TH17 cells by directly binding to the key transcription factor RORγt (Kd=1.13 μM). Dehydrolithocholic Acid Chemical Structure
  100. GC14905 Demethylasterriquinone B1

    DMAQ B1,L-783,281

    An insulin receptor (IR) activator

     Demethylasterriquinone B1 Chemical Structure
  101. GC74602 Depatuxizumab

    ABT-806

     Depatuxizumab is a brain-penetrant and humanized tumor-specific anti EGFR monoclonal antibody. Depatuxizumab Chemical Structure

Items 301 to 400 of 1359 total

per page
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6

Set Descending Direction